1 / 58

CORONARY STENT safety update & ROLE OF ENDOTHELIAL PROGENITOR CELL CAPTURING STENTS

CORONARY STENT safety update & ROLE OF ENDOTHELIAL PROGENITOR CELL CAPTURING STENTS. Giuseppe Biondi Zoccai, MD , FSICI-GISE University of Turin , Turin , Italy. Learnging goals. Scope of the problem Second generation drug-eluting stents

lane-gross
Download Presentation

CORONARY STENT safety update & ROLE OF ENDOTHELIAL PROGENITOR CELL CAPTURING STENTS

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. CORONARY STENT safety update & ROLE OF ENDOTHELIAL PROGENITOR CELL CAPTURING STENTS Giuseppe Biondi Zoccai, MD, FSICI-GISE University of Turin, Turin, Italy

  2. Learnginggoals • Scope of the problem • Second generation drug-eluting stents • Update on endothelial progenitor cell capturing stents

  3. Learnginggoals • Scope of the problem • Second generation drug-elutingstents • Update on endothelialprogenitorcellcapturingstents

  4. 25% Stent Thrombosis !

  5. The Stent Survived, thanks to...

  6. Learnginggoals • Scope of the problem • Second generation drug-elutingstents • Update on endothelialprogenitorcellcapturingstents

  7. 2nd generation DES: SPIRIT IV trial

  8. 2nd generation DES: COMPARE trial

  9. 2nd generation DES: COMPARE trial

  10. 2nd generation DES: COMPARE trial

  11. 2nd generation DES: COMPARE trial

  12. 2nd generation DES: COMPARE trial

  13. 2nd generation DES: COMPARE trial

  14. Learnginggoals • Scope of the problem • Second generation drug-elutingstents • Update on endothelialprogenitorcellcapturingstents

  15. Concept of EPC-capturing stent

  16. EPC Capture Stents

  17. EPC Capture Stents

  18. EPC Capture Stents

  19. Endothelialization of the Stent Struts: immediately after Stent Implantation accelerated endothelialization by EPC-“capturing”

  20. Pro-Healing Approach: EPC Capture Stent Endothelialization Genous Anti-CD34 coating BMS 7-days (%) 50 p=0.07 40 mean 30 20 mean 10 0 Genous BMS In rabbit iliac model

  21. Endothelialization and CD31 expression in SES with surface modification with anti-CD34 antibody stents vs. SES alone at 3 and14 days) SES-anti-CD34 SES alone 3 days 14 days Confocal

  22. EUROPE Austria 8 Belgium 3 Cyprus 2 Denmark 2 France 8 Germany 11 Greece 6 Ireland 1 Italy 26 Netherlands 5 Portugal 3 Spain 8 Switzerland 1 United Kingdom 9 NORTH AFRICA Tunisia 2 Czech Republic 5 Finland 1 Hungary 2 Poland 2 Romania 1 Russian Federation 5 MIDDLE EAST Egypt 6 Lebanon 1 Saudi Arabia 1 Syria 3 Turkey 3 LATIN AMERICA Venezuela 1 ASIA PACIFIC Australia 6 Hong Kong 1 Malaysia 9 Singapore 2 144 SITES

  23. e-HEALINGClinical Events in all Pats at 12 Months (n= 3196) Patients treated on or before Feb 22, 2007 All events reported before Aug 12, 2008; all events adjudicated by CEC Worst MACE per patient = cardiac death, MI, CABG, and clinically driven TLR

  24. e-HEALINGClinical Events in Diabetes at 12 Months (n= 851) Patients treated on or before Feb 22, 2007 All events reported before Aug 12, 2008; all events adjudicated by CEC Worst MACE per patient = cardiac death, MI, CABG, and clinically driven TLR

  25. e-HEALINGClinical Events at 12 Months (n= 2643) in Patients on Statins at Stent Implantation Patients treated on or before Feb 22, 2007 All events reported before Aug 12, 2008; all events adjudicated by CEC Worst MACE per patient = cardiac death, MI, CABG, and clinically driven TLR

  26. e-HEALINGClinical Events at 12 Months (n= 553) in Patients off Statins at Stent Implantation Patients treated on or before Feb 22, 2007 All events reported before Aug 12, 2008; all events adjudicated by CEC Worst MACE per patient = cardiac death, MI, CABG, and clinically driven TLR

  27. e-HEALING compared to the DES groups of a recent all-comers randomized study with no routine control angiography 1 All events reported before Aug 12, 2008; all events adjudicated by CEC; Worst MACE per patient = cardiac death, MI, CABG, and clinically driven TLR 2 MACE = Cardiac Death, MI TVR; The Lancet, 372: 1163 – 1173, 2008 3 MACE = any death, MI, TVR, Syntax Trial, presented at the ESC meeting in Munich, Sept. 2008 4 ARC definite + probable

  28. e-HEALING compared to the DES groups of a recent all-comers randomized study with no routine control angiography 1 All events reported before Aug 12, 2008; all events adjudicated by CEC; Worst MACE per patient = cardiac death, MI, CABG, and clinically driven TLR 2 MACE = Cardiac Death, MI TVR; The Lancet, 372: 1163 – 1173, 2008 3 MACE = any death, MI, TVR, Syntax Trial, presented at the ESC meeting in Munich, Sept. 2008 4 ARC definite + probable

  29. e-HEALING compared to the DES groups of a recent all-comers randomized study with no routine control angiography 1 All events reported before Aug 12, 2008; all events adjudicated by CEC; Worst MACE per patient = cardiac death, MI, CABG, and clinically driven TLR 2 MACE = Cardiac Death, MI TVR; The Lancet, 372: 1163 – 1173, 2008 3 MACE = any death, MI, TVR, Syntax Trial, presented at the ESC meeting in Munich, Sept. 2008 4 ARC definite + probable

  30. e-HEALING compared to the DES groups of a recent all-comers randomized study with no routine control angiography 1 All events reported before Aug 12, 2008; all events adjudicated by CEC; Worst MACE per patient = cardiac death, MI, CABG, and clinically driven TLR 2 MACE = Cardiac Death, MI TVR; The Lancet, 372: 1163 – 1173, 2008 3 MACE = any death, MI, TVR, Syntax Trial, presented at the ESC meeting in Munich, Sept. 2008 4 ARC definite + probable

  31. e-HEALING compared to the DES groups of a recent all-comers randomized study with no routine control angiography 1 All events reported before Aug 12, 2008; all events adjudicated by CEC; Worst MACE per patient = cardiac death, MI, CABG, and clinically driven TLR 2 MACE = Cardiac Death, MI TVR; The Lancet, 372: 1163 – 1173, 2008 3 MACE = any death, MI, TVR, Syntax Trial, presented at the ESC meeting in Munich, Sept. 2008 4 ARC definite + probable

  32. e-HEALING compared to the DES groups of a recent all-comers randomized study with no routine control angiography 1 All events reported before Aug 12, 2008; all events adjudicated by CEC; Worst MACE per patient = cardiac death, MI, CABG, and clinically driven TLR 2 MACE = Cardiac Death, MI TVR; The Lancet, 372: 1163 – 1173, 2008 3 MACE = any death, MI, TVR, Syntax Trial, presented at the ESC meeting in Munich, Sept. 2008 4 ARC definite + probable

  33. e-HEALING compared to the DES groups of a recent all-comers randomized study with no routine control angiography 1 All events reported before Aug 12, 2008; all events adjudicated by CEC; Worst MACE per patient = cardiac death, MI, CABG, and clinically driven TLR 2 MACE = Cardiac Death, MI TVR; The Lancet, 372: 1163 – 1173, 2008 3 MACE = any death, MI, TVR, Syntax Trial, presented at the ESC meeting in Munich, Sept. 2008 4 ARC definite + probable

  34. TRIAS-HR PilotStudy

  35. TRIAS-HR PilotStudy

  36. TRIAS-HR PilotStudy

  37. TRIAS-HR PilotStudy

  38. GENIUS-STEMI Trial

  39. GENIUS-STEMI Trial • Study flow chart 2007:400 P-PCI 100 patientsincluded (Randomization) 50 CrCo 50 GenousTM ASA 100mg/day+clopidogrel 75mg/day 30 days; GPIIb/IIIa inhibitors and thromboaspiration at the discretion of the physician 6-month clinical, angio and IVUS FU

  40. GENIUS-STEMI Trial • 6-monthclinicaloutcome GenousTM CrCo P=0.03 P=0.04 24 4 4 P=NS P=NS 10 2 2 P=NS 14 6 4 4 6 0 4 2 MACE CV Deaths MI TLR ST (Non hierachical)

More Related